USE OF ARTIFICIAL INTELLIGENCE IN A PULMONARY FIBROSIS CLINIC (LLM-ILD)

February 24, 2025 updated by: RICHELDI LUCA, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

USE OF ARTIFICIAL INTELLIGENCE IN THE BACK-OFFICE OF A SPECIALIZED MEDICAL CLINIC FOR PULMONARY FIBROSIS (LLM-ILD)

The present study aims to evaluate the usefulness of artificial intelligence (AI) in the back-office of an ILD (Interstitial Lung Disease) clinic.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

- Patients attending ILD clinic of the IRCCS Fondazione Policlinico A. Gemelli.

Exclusion Criteria:

  • Patients unable or unwilling to sign the informed consent
  • Patients who are senders of one of the emails chosen for the questionnaire
  • Patients with manifest inability to fill out the questionnaire

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Patients attending ILD clinic
Other: Survey
The patients will receive questionnaires. The enrolled patients will be asked to provide feedback on the answers they read.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Variation of VAS scores of clarity of the message in questionnaires administered at T1 and at T2
Time Frame: 15 days
15 days
Variation of VAS scores of empathy conveyed in questionnaires administered at T1 and at T2
Time Frame: 15 days
15 days

Secondary Outcome Measures

Outcome Measure
Time Frame
Percentage of answers recognised correctly as answers provided by AI among the total of answers flagged as provided by AI by study subjects
Time Frame: 1 day
1 day
Stratify the results by patients' demographic characteristics and past experiences with artificial intelligence systems.
Time Frame: 1 day
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 1, 2025

Primary Completion (Estimated)

September 1, 2025

Study Completion (Estimated)

February 1, 2026

Study Registration Dates

First Submitted

January 30, 2025

First Submitted That Met QC Criteria

February 24, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 24, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 7002 (CTEP)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe